Despite progress in discovering broad-spectrum antipicornavirus agents aided by X-ray crystal structures, no marketable drug has yet been developed.
No approved antipicornavirus drug yet; leaves open further development of clinical candidates.
Considerable efforts have been made over the past several years to discover a broad-spectrum antipicornavirus agent. The X-ray crystal structure of several rhinovirus serotypes, as well as a coxsackievirus, has provided valuable information with respect to the virus structure as well as the location of the binding site of several capsid-binding compounds. This has aided in the design of broad-spectrum compounds. Several potential drug candidates have reached clinical status and some progress has been made in achieving efficacy. However, none of these compounds has as yet become a marketable drug. This review summarizes the current status of efforts in this area.
No takes yet. Share an insight, caveat, or question.
Diana et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: